Orchestra BioMed Company Leadership
| OBIO Stock | 5.57 0.20 3.47% |
About 57% of all Orchestra BioMed's insiders are taking a long position. The analysis of the overall insider sentiment regarding Orchestra BioMed Holdings suggests that some insiders are bullish. Orchestra BioMed employs about 56 people. The company is managed by 11 executives with a total tenure of roughly 131 years, averaging almost 11.0 years of service per executive, having 5.09 employees per reported executive.
Orchestra BioMed's Insider Buying Vs Selling
57
Selling | Buying |
Latest Trades
| 2024-09-24 | David P Hochman | Acquired 2500 @ 4.91 | View | ||
| 2024-09-09 | Eric S Fain | Disposed 1800 @ 5.43 | View | ||
| 2024-09-06 | Eric S Fain | Disposed 2000 @ 5.64 | View | ||
| 2024-09-04 | Darren Sherman | Disposed 6837 @ 6.1 | View | ||
| 2024-08-14 | David P Hochman | Acquired 2500 @ 5.84 | View | ||
| 2024-06-25 | David P Hochman | Acquired 1000 @ 6.95 | View | ||
| 2024-05-30 | William Reed Little | Acquired 4000 @ 7 | View |
Monitoring Orchestra BioMed's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Orchestra |
Orchestra BioMed Management Team Effectiveness
The company has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Orchestra BioMed's management efficiency ratios could be used to measure how well Orchestra BioMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to drop to -0.64. At this time, Orchestra BioMed's Other Current Assets are very stable compared to the past year. As of the 26th of November 2024, Fixed Asset Turnover is likely to grow to 1.87, while Total Assets are likely to drop about 66.7 M.As of the 26th of November 2024, Common Stock Shares Outstanding is likely to drop to about 24.5 M. In addition to that, Net Loss is likely to drop to about (21.7 M)
Orchestra BioMed Workforce Comparison
Orchestra BioMed Holdings is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 69,802. Orchestra BioMed adds roughly 56.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Orchestra BioMed Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orchestra BioMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orchestra BioMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Orchestra BioMed insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orchestra BioMed Notable Stakeholders
An Orchestra BioMed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Orchestra BioMed often face trade-offs trying to please all of them. Orchestra BioMed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Orchestra BioMed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Hochman | Chairman Founder | Profile | |
| Darren Sherman | President Founder | Profile | |
| Yuval DSc | GM Therapies | Profile | |
| George Papandreou | Senior Therapies | Profile | |
| Avraham MD | Senior Innovation | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| HansPeter MD | Chief Officer | Profile | |
| Inessa Wheeler | Vice Marketing | Profile | |
| William Little | Executive Strategy | Profile | |
| Bob Laughner | Senior Quality | Profile | |
| Juan Lorenzo | Senior Development | Profile |
About Orchestra BioMed Management Performance
The success or failure of an entity such as Orchestra BioMed Holdings often depends on how effective the management is. Orchestra BioMed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Orchestra management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Orchestra management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | (0.72) | (0.69) |
Orchestra BioMed Workforce Analysis
Traditionally, organizations such as Orchestra BioMed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Orchestra BioMed within its industry.Orchestra BioMed Manpower Efficiency
Return on Orchestra BioMed Manpower
| Revenue Per Employee | 49.3K | |
| Revenue Per Executive | 250.9K | |
| Net Loss Per Employee | 877.1K | |
| Net Loss Per Executive | 4.5M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 7.1M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.